Covax-19™
Covax-19™ Uses, Dosage, Side Effects, Food Interaction and all others data.
Covax-19™, a protein-based vaccine, was developed through partnership between APC and Vaxine. It uses an insect-cell-produced recombinant SARS-CoV-2 spike protein and Vaxine’s adjuvant, Advax-SM. This adjuvant is designed to circumvent high fevers, fatigue, and aches experienced with other vaccines using more traditional adjuvants. Covax-19™ was tested in animal studies, and shown to achieve potent antibody and T-cell responses against the COVID-19 spike protein. As of June 2020, the vaccine is in Phase 1 trials to evaluate safety and immune responses (NCT04428073). Phase 2 and 3 trials are planned for September 2020, and the vaccine is expected to launch early in 2021.
| Trade Name | Covax-19™ |
| Generic | Covax-19™ |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Covax-19™
